OTC Markets OTCPK - Delayed Quote USD
Propanc Biopharma, Inc. (PPCB)
6.46
+0.96
+(17.45%)
At close: April 23 at 4:00:00 PM EDT
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Expense
1,184.94
1,536.05
1,776.65
1,990.87
1,812.14
Operating Income
-1,184.94
-1,536.05
-1,776.65
-1,990.87
-1,812.14
Net Non Operating Interest Income Expense
-428.29
-665.78
-532.79
-563.19
-449.46
Other Income Expense
-57.06
252.17
-480.98
-159.01
122.24
Pretax Income
-1,670.28
-1,949.66
-2,790.41
-2,713.06
-2,139.36
Tax Provision
-0.51
-129.13
-129.84
-54.98
-113.42
Net Income Common Stockholders
-1,685.57
-2,013.49
-3,126.84
-3,358.43
-2,417.70
Diluted NI Available to Com Stockholders
-1,685.57
-2,013.49
-3,126.84
-3,358.43
-2,417.70
Basic EPS
-128.03
-1.20k
-31.27k
-1.12M
-800.00
Diluted EPS
-128.03
-1.20k
-31.27k
-1.12M
-800.00
Basic Average Shares
13.17
1.42
0.10
0
3.03
Diluted Average Shares
13.17
1.42
0.10
0
3.03
Total Operating Income as Reported
-1,184.94
-1,536.05
-1,776.65
-1,990.87
-1,812.14
Rent Expense Supplemental
34.86
34.15
28.84
28.37
28.11
Total Expenses
1,184.94
1,536.05
1,776.65
1,990.87
1,812.14
Net Income from Continuing & Discontinued Operation
-1,669.77
-1,820.53
-2,660.57
-2,658.09
-2,025.95
Normalized Income
-1,612.73
-2,056
-2,201.97
-2,502.30
-2,141.70
Interest Income
0.03
0.06
0.04
5.61
0
Interest Expense
428.32
665.84
532.82
568.80
449.46
Net Interest Income
-428.29
-665.78
-532.79
-563.19
-449.46
EBIT
-1,241.97
-1,283.82
-2,257.59
-2,144.27
-1,689.91
EBITDA
-1,221.56
-1,262.16
-2,234.66
-2,138.60
-1,687.91
Reconciled Depreciation
20.40
21.66
22.93
5.67
1.99
Net Income from Continuing Operation Net Minority Interest
-1,669.77
-1,820.53
-2,660.57
-2,658.09
-2,025.95
Total Unusual Items Excluding Goodwill
-57.06
252.17
-480.98
-159.01
122.24
Total Unusual Items
-57.06
252.17
-480.98
-159.01
122.24
Normalized EBITDA
-1,164.51
-1,514.33
-1,753.68
-1,979.59
-1,810.15
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-0.02
16.70
-22.38
-3.22
6.48
6/30/2021 - 1/7/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ENDV Endonovo Therapeutics, Inc.
0.0002
0.00%
KTTA Pasithea Therapeutics Corp.
1.6300
+5.84%
KZIA Kazia Therapeutics Limited
3.3250
-3.76%
SONN Sonnet BioTherapeutics Holdings, Inc.
1.4200
+9.23%
GBLX GB Sciences, Inc.
0.0002
0.00%
CDT Conduit Pharmaceuticals Inc.
0.5565
-4.22%
VRTX.MX Vertex Pharmaceuticals Incorporated
9,360.00
0.00%
ARTH Arch Therapeutics, Inc.
0.1608
0.00%
MTEM Molecular Templates, Inc.
0.0001
0.00%
RADX Radiopharm Theranostics Limited
4.0500
-3.34%